RxDoctor Payments Data

Andrew Lai, MD

Internal Medicine · San Diego, CANPI 1003983958

Payments from drug & device makers

$2,663in general payments, 2019–2025

Across 119 payments — averaging $22.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$326
  • Amgen$323
  • AbbVie$249
  • Novartis$228
  • Pfizer$223
  • Novo Nordisk$191
  • plus $1K from 20 others

What the payments were for

  • Speaking & faculty fees$532%
  • Food & beverage$2,58097%
  • Education$301%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,663 in reported general payments places this provider in the 85th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$146,698
Medicare patients
192
Services billed
20,169

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban51$73,431
MounjaroTirzepatide67$72,006
JardianceEmpagliflozin29$53,443
TrulicityDulaglutide13$27,519
XareltoRivaroxaban20$18,763
Dexlansoprazole DrDexlansoprazole13$6,299
SynthroidLevothyroxine Sodium41$4,157
Atorvastatin Calcium177$1,574
Wixela InhubFluticasone Propion/Salmeterol14$1,501
Rosuvastatin Calcium135$1,453
PaxlovidNirmatrelvir/Ritonavir18$1,429
Ezetimibe45$1,403
Fluticasone-SalmeterolFluticasone Propion/Salmeterol12$1,256
Tamsulosin Hcl72$1,248
Valsartan46$1,051

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$326$99,52480 claims
PfizerEliquis, Paxlovid$223$74,86069 claims
Johnson & JohnsonXarelto$96$18,76320 claims
AbbVieSynthroid$249$4,15741 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 13,581 internal medicine providers in California.

Other internal medicine in San Diego

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →